アリゾナ州における慢性リンパ性白血病の臨床試験
アリゾナ州内の拠点で、慢性リンパ性白血病に関する15件の研究が参加者を募集しています。
アリゾナ州内の都市
公式研究テキスト（英語）
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Kingman Regional Medical Center, Kingman
- Cancer Center at Saint Joseph's, Phoenix
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Mayo Clinic in Arizona, Scottsdale
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT03516617Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT04269902A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- GC2202 Study Site 118, Bullhead City
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT05645107A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Honor Health Research Institute, Scottsdale
- University of Arizona Cancer Center, Tucson
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05006716A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Mayo Clinic Phoenix, Phoenix
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06973187A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Banner MD Anderson Cancer Center ( Site 0059), Gilbert
- Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0051), Phoenix
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06136559A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Arizona Oncology Associates, P.C. - HOPE, Tucson
被験者募集中第4相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07218341A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Banner MD Anderson Cancer Center, Phoenix
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07221500Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope - Phoenix, Goodyear
- Mayo Clinic, Phoenix
- Honor Health, Scottsdale
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/03更新 · NCT04588922A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Ironwood Cancer & Research Centers, Chandler
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/19更新 · NCT06588478A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Arizona Oncology - Tucson - Rudasill /ID# 267552, Tucson
- Southern VA Health Care System /ID# 266254, Tucson
被験者募集中第3相
18歳以上 · 全性別 · 2026/04/09更新 · NCT06428019The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
- Mayo Clinic in Arizona, Scottsdale
被験者募集中健康なボランティア歓迎
18歳〜80歳 · 全性別 · 2026/04/09更新 · NCT05876923Study of SGR-1505 in Mature B-Cell Neoplasms
- Banner Health - MD Anderson Cancer Center, Gilbert
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT05544019Q702 for the Treatment of Patients With Hematologic Malignancies
- Mayo Clinic in Arizona, Scottsdale
被験者募集中第1相
18歳以上 · 全性別 · 2025/10/10更新 · NCT06712810ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。